<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    Aramchol news dated 09/17/2024
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        9/18/2024 01:55am
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">The latest news on Aramchol, as of September 17, 2024, is that Galmed Pharmaceuticals has announced the grant of a new patent for the combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the treatment of NASH and liver fibrosis. This patent extends the patent protection of Aramchol until September 2039, providing legal and regulatory support for the drug's development and potential market entry. The patent news, combined with the positive clinical trial results for Aramchol in NASH, could be contributing to the surge in Galmed Pharmaceuticals' stock price on September 17, 2024.</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$){return {layout:"default",data:[{noData:d,currentQuestion:e,textDescription:F,comeFrom:"AInvestShareLink",events:g,answerSource:i}],fetch:{},error:g,state:{sharePreviewModule:{loadJgySuccess:G,dialogRenderList:[{originAnswer:{input_media_info:[],agent_id:a,output_media_info:[],task_id:a,source:i,reply_action:"Answer",execute_mode:o,param:"{\"trace_id\":\"20003020172659574974800000000876\",\"question\":\"Aramchol news dated 09\u002F17\u002F2024\",\"user_id\":\"1802138051\",\"user_name\":\"\",\"input_type\":\"typewrite\",\"session_id\":\"9e5d030ce417cf0676f53c8947f2c55e\",\"source\":\"ths_wencai_international\"}",agent_info:[{info_type:p,title:q,full_summary:H,summary:I,url:r,image_url:a,video_url:a,publish_time:j,raw_data:{number:J,title:q,full_summary:H,url:r,image_url:a,video_url:a,publish_time:j}},{info_type:p,title:s,full_summary:a,summary:K,url:t,image_url:a,video_url:a,publish_time:L,raw_data:{number:M,title:s,full_summary:a,url:t,image_url:a,video_url:a,publish_time:L}},{info_type:p,title:u,full_summary:N,summary:O,url:v,image_url:a,video_url:a,publish_time:j,raw_data:{number:P,title:u,full_summary:N,url:v,image_url:a,video_url:a,publish_time:j}}],answer_chain_name:Q,come_from:"iOSScreenerQuoteLite",text_answer:F,trace_id:w,cost:17213,question:e,fallback_type:R,input_type:S,fall_back_reason:{fall_back_type:R,risk_detail:{matched_words:[]}},session_id:x,first_return_cost:3658,transfer_question:e,start_time:T,remote_svc:"jgateway",slots:[],answer_type:o,user_id:k,skill_name:U},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",base_info:{trace_id:w,session_id:x,user_id:k,question:e,source:i,raw_question:e,version:"3.4.1"},extra:{}},{answer_path:l,section:{id:m,info_texts:["Thinking"],show_type:n,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},extra:{}},{answer_path:l,section:{id:m,info_texts:["Searching Web: Aramchol news dated 09\u002F17\u002F2024"],show_type:n,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"thinking"},extra:{}},{answer_path:c,section:{id:V,info_texts:[],show_type:y,choice:[],result_page:{},tag_info_list:[],is_last:b},extra:{}},{answer_path:c,section:{id:V,info_texts:[],show_type:y,choice:[],result_page:{},tag_info_list:[],is_last:b},extra:{}},{answer_path:l,section:{id:m,info_texts:["Generating Answer"],show_type:n,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},extra:{}},{answer_path:c,section:{id:h,info_texts:[],show_type:f,voice_txt:"The",text_answer:W,rich_text:W,choice:[],result_page:{},tag_info_list:[],is_last:b},extra:{}},{answer_path:c,section:{id:z,info_texts:[],show_type:f,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:r,title:q,summary:I,index:J}],is_last:b},extra:{}},{answer_path:c,section:{id:h,info_texts:[],show_type:f,voice_txt:". This",text_answer:X,rich_text:X,choice:[],result_page:{},tag_info_list:[],is_last:b},extra:{}},{answer_path:c,section:{id:z,info_texts:[],show_type:f,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:t,title:s,summary:K,index:M}],is_last:b},extra:{}},{answer_path:c,section:{id:h,info_texts:[],show_type:f,voice_txt:", providing",text_answer:Y,rich_text:Y,choice:[],result_page:{},tag_info_list:[],is_last:b},extra:{}},{answer_path:c,section:{id:z,info_texts:[],show_type:f,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:v,title:u,summary:O,index:P}],is_last:b},extra:{}},{answer_path:c,section:{id:h,info_texts:[],show_type:f,voice_txt:A,text_answer:A,rich_text:A,choice:[],result_page:{},tag_info_list:[],is_last:b},extra:{}},{answer_path:c,section:{id:1002,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:"GLMD",market_id:"186",name:Z,domain:"stock"},pos:63,section_id:h,txt:Z}],is_last:b},extra:{}},{answer_path:l,section:{id:m,info_texts:["Completed"],show_type:n,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:_,choice:[],result_page:{},tag_info_list:[],is_last:b},extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10001,info_texts:[],show_type:_,choice:[{display_text:B,query_text:B,trace_info:{item_id:"b8d9c4534e1fe6bc1934f36342fe1acc",item_type:C,item_name:B,rec_info:"2+507_496_21_130+0+0+20003020172659574974800000000876+b8d9c4534e1fe6bc1934f36342fe1acc+llm_generated+aimeTagAnalysis+0+0.004038657061755657+1"}},{display_text:D,query_text:D,trace_info:{item_id:"6fe2b1841003722306dc64234d9936e5",item_type:C,item_name:D,rec_info:"2+507_496_21_130+0+0+20003020172659574974800000000876+6fe2b1841003722306dc64234d9936e5+llm_generated+aimeTagAnalysis+0+0.0031001479364931583+2"}},{display_text:E,query_text:E,trace_info:{item_id:"7b79e47179d49d33d1df69e157db8ede",item_type:C,item_name:E,rec_info:"2+507_496_21_130+0+0+20003020172659574974800000000876+7b79e47179d49d33d1df69e157db8ede+llm_generated+aimeTagAnalysis+0+0.003000380704179406+3"}}],result_page:{},tag_info_list:[],is_last:b},extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1005,info_texts:[],show_type:y,choice:[],result_page:{},tag_info_list:[],is_last:b},extra:{action_name:U,with_paid_index:d,no_refresh_answer:d,answer_source:{execute_mode:o,answer_chain_name:Q}},is_last:b}],questionItem:{data:{qStr:e,encodeFlag:d,imageData:g,docsData:[],quoteData:g},tplType:"question"},events:void 0,agentId:a,param:{trace_id:w,question:e,user_id:k,user_name:a,input_type:S,session_id:x,source:i}}],userId:k,userName:a,startTime:T,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:g,endSignal:d,theme:"white",showTracePopup:d,traceListData:[],chatTraceTargetIndex:G,traceTableData:g,showMask:d}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Faramchol-news-dated-09172024-f36545\u002F",config:{_app:{basePath:$,assetsPath:$,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,"other\u002FopenAnswer",false,"Aramchol news dated 09\u002F17\u002F2024","rich_text",null,2001,"ths_wencai_international","2024-09-17","1802138051","progress\u002Fsearching_for",1000,"searching_for","agent","search","Galmed Pharmaceuticals Ltd. (GLMD)","https:\u002F\u002Fstockanalysis.com\u002Fstocks\u002Fglmd\u002F","Galmed Announces Grant of New Patent for the ...","https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Fgalmed-announces-grant-of-new-patent-for-the-combination-of-aramchol-with-resmetirom-mgl-3196-rezdiffra-for-the-treatment-of-nash-and-liver-fibrosis-302090340.html","Galmed Pharmaceuticals Ltd. (GLMD) Stock Price, News ...","https:\u002F\u002Ffinance.yahoo.com\u002Fquote\u002FGLMD\u002F","20003020172659574974800000000876","9e5d030ce417cf0676f53c8947f2c55e","signal",2000,".","How does the Aramchol news impact the company's stock price?","llm_generated","How does the Aramchol news relate to the company's financial performance?","What are the key details in the Aramchol news?","The latest news on Aramchol, as of September 17, 2024, is that Galmed Pharmaceuticals has announced the grant of a new patent for the combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the treatment of NASH and liver fibrosis. This patent extends the patent protection of Aramchol until September 2039, providing legal and regulatory support for the drug's development and potential market entry. The patent news, combined with the positive clinical trial results for Aramchol in NASH, could be contributing to the surge in Galmed Pharmaceuticals' stock price on September 17, 2024.",0,"Sep 17, 2024, 1:54 PM EDT - Market open","Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis. TEL ...",3,"With this latest patent, Galmed is strengthening and extending the patent protection of its lead compound, Aramchol, until September 2039.","2024-03-14",2,"Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel. www.galmedpharma.com","The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In ...",1,"agent_common_v2\nagent-summary","NONE","typewrite",1726595749752,"search news",999,"The latest news on Aramchol, as of September 17, 2024, is that Galmed Pharmaceuticals has announced the grant of a new patent for the combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the treatment of NASH and liver fibrosis[^3]",". This patent extends the patent protection of Aramchol until September 2039[^2]",", providing legal and regulatory support for the drug's development and potential market entry. The patent news, combined with the positive clinical trial results for Aramchol in NASH, could be contributing to the surge in Galmed Pharmaceuticals' stock price on September 17, 2024[^1]","Galmed","choice","\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>